Drug Shortage Report for BRILINTA
| Report ID | 257663 |
| Drug Identification Number | 02368544 |
| Brand name | BRILINTA |
| Common or Proper name | Common or Proper name |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | TICAGRELOR |
| Strength(s) | 90MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | Packaging size |
| ATC code | B01AC |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | 2023-09-14 |
| Actual start date | 2023-03-08 |
| Estimated end date | 2027-09-17 |
| Actual end date | 2029-09-16 |
| Shortage status | Actual shortage |
| Updated date | 2025-11-12 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: [email protected]. Veuillez contacter le Service d'information médicale d'AstraZeneca Canada pour toute question spécifique au 1-800-668-6000 (EN) ou au 1-800-461-3787 (FR) ou par courriel : [email protected]. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2025-11-12 | French | Compare |
| v3 | 2025-11-12 | English | Compare |
| v2 | 2025-11-10 | French | Compare |
| v1 | 2025-11-10 | English | Compare |
Showing 1 to 4 of 4